Alembic Pharmaceuticals Limited (IN:APLLTD)
:APLLTD
Want to see IN:APLLTD full AI Analyst Report?
Top Page
Alembic Pharmaceuticals Limited
(APLLTD)
Select Model
Select Model
Rating:57Neutral
Price Target:
₹791.00
▼(-14.97% Downside)
Action:ReiteratedDate:03/24/26
The score is driven by mixed financial performance (better profitability trends but weak cash flow and higher leverage risk) and a weak technical setup (below key moving averages with negative MACD). Valuation is not compelling at ~31x earnings, though the dividend provides some support.
Positive Factors
Consistent revenue growth
A sustained ~13.2% revenue growth rate signals expanding market share and product adoption across geographies. Over a 2–6 month horizon this supports scale benefits, steady top-line momentum, and underpins reinvestment capacity for R&D and commercialization initiatives.
Negative Factors
Declining free cash flow
Rising capex and a falling free cash flow to net income ratio weaken cash generation. Over months this reduces financial flexibility for dividends, M&A or R&D funding and raises the probability the firm must rely more on external financing or slower organic investment pacing.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent revenue growth
A sustained ~13.2% revenue growth rate signals expanding market share and product adoption across geographies. Over a 2–6 month horizon this supports scale benefits, steady top-line momentum, and underpins reinvestment capacity for R&D and commercialization initiatives.
Read all positive factors
Alembic Pharmaceuticals Limited (APLLTD) vs. iShares MSCI India ETF (INDA)
Market Cap
₹147.64B
Dividend Yield1.28%
Average Volume (3M)9.71K
Price to Earnings (P/E)31.3
Beta (1Y)1.04
Revenue Growth13.20%
EPS Growth4.00%
CountryIN
Employees14,858
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)8.70
Shares Outstanding196,563,130
10 Day Avg. Volume3,953
30 Day Avg. Volume9,706
Financial Highlights & Ratios
PEG Ratio-5.74
Price to Book (P/B)3.40
Price to Sales (P/S)2.64
P/FCF Ratio-37.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)41.24
Revenue Forecast (FY)₹82.36B
Alembic Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in v...
How the Company Makes Money
Alembic Pharmaceuticals makes money primarily by selling pharmaceutical products and related supplies through multiple revenue streams: (1) Branded formulations (domestic): The company markets prescription medicines under its own brands in India a...
Alembic Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
72
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 70.83B | 66.72B | 62.29B | 56.53B | 53.06B | 53.93B |
| Gross Profit | 45.89B | 47.91B | 44.33B | 38.78B | 38.08B | 40.53B |
| EBITDA | 11.16B | 9.89B | 9.14B | 6.96B | 8.59B | 14.66B |
| Net Income | 6.34B | 5.83B | 6.16B | 3.42B | 5.21B | 11.46B |
Balance Sheet | ||||||
| Total Assets | 83.97B | 77.73B | 64.46B | 61.83B | 71.22B | 67.09B |
| Cash, Cash Equivalents and Short-Term Investments | 1.55B | 901.00M | 1.20B | 754.80M | 610.90M | 2.85B |
| Total Debt | 14.89B | 12.57B | 5.13B | 7.22B | 7.17B | 5.84B |
| Total Liabilities | 30.81B | 25.83B | 16.27B | 18.12B | 18.84B | 16.42B |
| Stockholders Equity | 53.19B | 51.91B | 48.18B | 43.70B | 52.38B | 50.67B |
Cash Flow | ||||||
| Free Cash Flow | 1.69B | -4.76B | 4.76B | 2.81B | 1.27B | 8.04B |
| Operating Cash Flow | 4.03B | 879.70M | 8.03B | 7.24B | 5.52B | 14.63B |
| Investing Cash Flow | -2.87B | -5.68B | -3.21B | -4.48B | -3.72B | -8.39B |
| Financing Cash Flow | -649.70M | 4.44B | -4.38B | -2.62B | -2.17B | -5.97B |
Alembic Pharmaceuticals Limited Technical Analysis
Positive
930.30
Price Trends
727.19
Positive
785.82
Negative
869.39
Negative
Market Momentum
9.50
Negative
67.55
Neutral
92.98
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:APLLTD, the sentiment is Positive. The current price of 930.3 is above the 20-day moving average (MA) of 693.45, above the 50-day MA of 727.19, and above the 200-day MA of 869.39, indicating a neutral trend. The MACD of 9.50 indicates Negative momentum. The RSI at 67.55 is Neutral, neither overbought nor oversold. The STOCH value of 92.98 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:APLLTD.
Alembic Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹195.67B | 26.69 | ― | 0.57% | 6.63% | -16.51% | |
71 Outperform | ₹86.21B | 18.03 | ― | 0.44% | 13.29% | -2.17% | |
66 Neutral | ₹321.75B | 36.01 | ― | 0.86% | 9.47% | 17.05% | |
63 Neutral | ₹418.95B | 35.44 | ― | 2.16% | 2.59% | 18.83% | |
62 Neutral | ₹150.43B | 76.03 | ― | 0.46% | 12.09% | -31.01% | |
57 Neutral | ₹147.64B | 31.27 | ― | 1.28% | 13.20% | 4.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:APLLTD
Alembic Pharmaceuticals Limited
764.05
-97.75
-11.34%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,445.10
-366.95
-13.05%
IN:JBCHEPHARM
JB Chemicals & Pharmaceuticals Ltd.
2,047.85
464.14
29.31%
IN:JUBLPHARMA
Jubilant Pharmova Limited
954.80
51.06
5.65%
IN:MARKSANS
Marksans Pharma Limited
191.95
-25.48
-11.72%
IN:NATCOPHARM
NATCO Pharma Limited
1,090.10
211.26
24.04%
Alembic Pharmaceuticals Limited Corporate Events
Alembic Pharmaceuticals Announces Death of Senior Delhi-Based Director
Apr 27, 2026
Alembic Pharmaceuticals has announced the death of Mr. Saibal Mukherjee, who served as Resident Director at its Delhi office and had been with the company since 2014. The company described him as an integral part of the organisation and noted that...
Alembic Pharma Wins USFDA Nod for Generic Multiple Sclerosis Drug
Apr 25, 2026
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Fingolimod Capsules 0.5 mg, a generic version of Novartis’s Gilenya used to treat relapsing forms of mu...
Alembic Pharma Wins USFDA Nod for Methotrexate Injection in Key U.S. Generics Boost
Apr 16, 2026
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its Methotrexate Injection USP in 50 mg/2 mL multi-dose vials and 1 g/40 mL single-dose vials, which are therapeutically equivalent to Hospira Inc....
Alembic Pharmaceuticals Forms Thailand Subsidiary to Expand Southeast Asia Footprint
Mar 9, 2026
Alembic Pharmaceuticals Limited has incorporated a new wholly owned subsidiary, Alembic Pharmaceuticals (Thailand) Co., Ltd., in Thailand with a share capital of THB 3 million. The subsidiary, which has yet to commence operations, will focus on pr...
Alembic Pharma Wins USFDA Nod for $500 Million Efinaconazole Generic
Feb 24, 2026
Alembic Pharmaceuticals Limited has received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Efinaconazole Topical Solution, 10%, a generic version of Bausch Health Americas Inc.’s Jublia,...
Alembic Pharmaceuticals Board Clears Q3 FY26 Unaudited Results, Appoints New Non-Executive Director
Feb 5, 2026
Alembic Pharmaceuticals Limited’s Board of Directors has approved the unaudited consolidated and standalone financial results for the quarter and nine months ended 31 December 2025, along with the corresponding limited review reports from th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.